BAY BANKS OF VIRGINIA INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits

Edgar Glimpses |

Item 8.01 Other Events.

On June 25, 2014, Bay Banks of Virginia, Inc. (the "Company"), the holding company for Bank of Lancaster (the "Bank"), issued a press release announcing that Randolph N. Reynolds, Jr. has been elected to the Bank's Board of Directors.

Mr. Reynolds is a co-founder and partner in Reynolds Development, LLC, a private real estate management and development company. Prior to the sale of Reynolds Metals Company to Alcoa, Mr. Reynolds served in numerous management positions with Reynolds Metals Company. At the time of the sale, he was the Director of Sales and Marketing. Mr. Reynolds is a Richmond native and he received a B.A. in Economics from the College of William and Mary.

A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. Exhibit No. Description 99.1 Press release, June 25, 2014.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
STPJF Southern Pacific Resource Corp 0.00 0.00 0.00 0

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.